Keywords: remicade, now, available, crohn, first, market, centocor
Remicade Now Available For Crohn's In First Market
Article | 15 October 1998
Centocor has launched its antitumor necrosis factor alpha antibodyRemicade (infliximab) in the USA for the treatment of moderate-to-severe Crohn's disease.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
